By using the MapQuant test, not only to determine the genomic grade but also to assess the prognostic and predictive markers ER, PR and HER2, we could potentially get a more reliable and informative determination of tumour characteristics compared to the immune-histochemistry assessments, therefore leading to a more reliable treatment decision. This evidence concerns the gene ERBB2 and neoplasm.